The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Four Pharmas Launch Filgrastim, Third Biosimilars in Japan
June 3, 2013
-
ACADEMIA Japan College of Rheumatology to Collaborate with Pfizer on PMS, Warns that Non-RA Specialists More Inclined to Prescribe Xeljanz
May 31, 2013
-
BUSINESS Astellas, Amgen Clinch Strategic Alliance on 5 Products; JV to Begin Operations in October
May 30, 2013
-
BUSINESS Ex-Novartis Employee Attended Key Panel Meetings for Diovan Trial
May 29, 2013
-
BUSINESS MTPC Files NDA for SGLT-2 Inhibitor Canagliflozin in Japan
May 29, 2013
-
REGULATORY PAFSC’s Second Committee Recommends Approval for IV Preparation of Acetaminophen
May 28, 2013
-
BUSINESS 2012 Earnings: Foreign Pharmas’ Japan Units Underperform Market Growth, Operating Profit Down 21%
May 27, 2013
-
REGULATORY First Committee Recommends Approval for Third GLP-1 Receptor Agonist Lyxumia, Others
May 27, 2013
-
REGULATORY Citations in Guidelines to Be Prerequisite for Health Coverage of Off-Label Drugs under 1980 Notification
May 24, 2013
-
BUSINESS Japan’s 1st Western Herbal Medicine Antistax to Hit Shelves in June: SSP
May 24, 2013
-
ORGANIZATION Towa’s Yoshida Appointed New JGA President, Says Achieving Roadmap Goals Important
May 23, 2013
-
BUSINESS AZ Oncology Division to Provide Information Based on Patients’ Lifestyle
May 22, 2013
-
BUSINESS Domestic Sales of Ethical Drugs Rose 0.3% to 9,560.1 Billion Yen in FY2012: IMS Japan
May 22, 2013
-
BUSINESS Allegra AGs Pitched as Affordable Original Drugs with Production by Sanofi
May 21, 2013
-
BUSINESS Takeda Slips to 3rd Place in 25 Major Pharmas’ Operating Profit Ranking
May 20, 2013
-
BUSINESS FY2012 Sales Up 18% for Both Generic-Only Makers, Research-Driven Pharmas’ Generic Units; Govt Incentive Measures Biggest Contributor
May 17, 2013
-
BUSINESS FY2012 Japan Pharma Market: Sales of Major Long-Listed Drugs Tumble 30-40%
May 16, 2013
-
REGULATORY CSIMC Approves Listing of 15 New APIs/19 Products Including Pfizer’s Xeljanz with Expected Peak Sales of 59.7 Billion Yen
May 16, 2013
-
BUSINESS Eight Companies Initiate Voluntary Recall of Enalapril Generics Due to Deviations from Specifications
May 15, 2013
-
BUSINESS Four Leading Wholesalers See Clear Recovery in Pharmaceutical Wholesale Business
May 14, 2013
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…